Imugene Statistics
Total Valuation
Imugene has a market cap or net worth of 46.54 million. The enterprise value is 34.94 million.
| Market Cap | 46.54M |
| Enterprise Value | 34.94M |
Important Dates
The next estimated earnings date is Thursday, August 28, 2025.
| Earnings Date | Aug 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 288.50M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +10.54% |
| Shares Change (QoQ) | +1.54% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 254.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -40.88 |
| PB Ratio | 1.19 |
| P/TBV Ratio | 2.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.44 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.55 |
Financial Position
The company has a current ratio of 3.08, with a Debt / Equity ratio of 0.25.
| Current Ratio | 3.08 |
| Quick Ratio | 1.96 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.15 |
| Interest Coverage | -403.24 |
Financial Efficiency
Return on equity (ROE) is -100.19% and return on invested capital (ROIC) is -53.79%.
| Return on Equity (ROE) | -100.19% |
| Return on Assets (ROA) | -42.92% |
| Return on Invested Capital (ROIC) | -53.79% |
| Return on Capital Employed (ROCE) | -127.75% |
| Revenue Per Employee | -227,687 |
| Profits Per Employee | -16.00M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.20% in the last 52 weeks. The beta is 3.39, so Imugene's price volatility has been higher than the market average.
| Beta (5Y) | 3.39 |
| 52-Week Price Change | -86.20% |
| 50-Day Moving Average | 0.33 |
| 200-Day Moving Average | 0.75 |
| Relative Strength Index (RSI) | 36.25 |
| Average Volume (20 Days) | 14,058 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imugene had revenue of -1.14 million and -80.02 million in losses. Loss per share was -0.37.
| Revenue | -1.14M |
| Gross Profit | -1.14M |
| Operating Income | -74.66M |
| Pretax Income | -80.02M |
| Net Income | -80.02M |
| EBITDA | -72.29M |
| EBIT | -74.66M |
| Loss Per Share | -0.37 |
Balance Sheet
The company has 20.88 million in cash and 9.75 million in debt, giving a net cash position of 11.13 million.
| Cash & Cash Equivalents | 20.88M |
| Total Debt | 9.75M |
| Net Cash | 11.13M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 39.16M |
| Book Value Per Share | 0.18 |
| Working Capital | 34.11M |
Cash Flow
In the last 12 months, operating cash flow was -56.89 million and capital expenditures -6.26 million, giving a free cash flow of -63.15 million.
| Operating Cash Flow | -56.89M |
| Capital Expenditures | -6.26M |
| Free Cash Flow | -63.15M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | 6,557.96% |
| Pretax Margin | 7,028.94% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Imugene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.54% |
| Shareholder Yield | n/a |
| Earnings Yield | -171.92% |
| FCF Yield | -135.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 2, 2025. It was a reverse split with a ratio of 0.0294118.
| Last Split Date | Jul 2, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.0294118 |
Scores
Imugene has an Altman Z-Score of -1.35 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.35 |
| Piotroski F-Score | 1 |